A few weeks ago, I got a call from Mark, the director of a mid-sized independent lab in Ohio. He was staring at his Q1 numbers and doing the math on what January 2027 would look like if PAMA cuts actually hit. “We’re looking at losing fourteen percent on our top twenty CPT codes,” he told me. “That’s nearly $400,000 in annual revenue. I might have to cut two techs and stop offering STAT chemistry.”

I hear versions of this call every month. After fifteen years of working in the laboratory billing services  industry and watching labs navigate reimbursement earthquakes, I can tell you this: the PAMA cuts scheduled for 2027 aren’t just a policy headline. They’re an existential threat to your revenue cycle. And the RESULTS Act? It’s either the parachute that saves you or the political football that drops you.

The PAMA reality check

In 2014, Congress passed the Protecting Access to Medicare Act to align Medicare lab payments with private market rates. Reasonable idea, disastrous execution.

CMS collected data from a tiny fraction of mostly large labs with deeply discounted contracts, so weighted median rates came in artificially low. The result? Nearly $4 billion in cuts between 2018 and 2020, with some tests slashed by up to 30 percent.

Congress delayed the next round six times. The 2026 package pushed the 15 percent reductions to January 2027. But a delay is not a fix. Without permanent reform, your lab faces 15 percent cuts in 2027, another in 2028, and another in 2029.

For a lab doing $3 million in Medicare revenue, that’s amputation.

The data disaster

The core problem with PAMA isn’t just the cuts. It’s the data.

CMS used private payor data from less than one percent of all laboratories. Hospital outreach labs and physician office labs were barely represented. The 2026 package updated the reporting window to 2025 data, which helps. But the structural flaw remains. If your payer mix includes higher-complexity molecular testing, toxicology, or pathology, the methodology doesn’t capture your true cost structure. It captures whatever rock-bottom rates the largest national labs accept. Your reimbursement is being set by data that doesn’t reflect your reality.

The RESULTS Act lifeline

The Reforming and Enhancing Sustainable Updates to Laboratory Testing Services Act, RESULTS for short, is bipartisan legislation with real teeth.

First, it caps annual cuts at 5 percent instead of 15. Second, it shifts rate-setting to independent commercial claims databases so hospital outreach labs, independent labs, and physician office labs all get represented; not just the giants. Third, it freezes CLFS rates at 2025 levels through 2028 and pushes new rates to 2029 based on 2027 data. That gives you four years of predictable reimbursement to plan investments, staffing, and service lines. Fourth, it excludes Medicaid managed care rates from the calculation. Those rates are often artificially low and have been dragging down the weighted median.

The revenue cycle ripple

Most lab owners think about PAMA at the macro level: “Will my Medicare rates drop?” But the real damage happens downstream.

When reimbursement drops 15 percent on 800 commonly ordered tests, your AR team doesn’t just collect less. They collect slower. Payers become more aggressive with denials. Labs write off more patient balances. I’ve seen labs with clean billing operations watch their days in AR balloon from 32 to 51 days after a rate cut. One Texas lab saw their denial rate jump from 8 percent to 19 percent. Payers scrutinized every claim more aggressively, knowing labs were under pressure. That lab spent $40,000 in overtime just to recover revenue they used to collect automatically.

What happens if Congress fails

The RESULTS Act has bipartisan support, but that doesn’t guarantee passage. If Congress kicks the can again, 15 percent cuts hit nearly 800 CPT codes in January 2027. Commercial payers will renegotiate contracts downward using Medicare as a benchmark. Rural labs will close STAT services. By 2028, the industry will become a consolidation feeding frenzy. Small and mid-sized labs either sell to national chains or shutter. The survivors are the ones with ironclad revenue cycle systems and enough cash reserves to weather the storm.

The solution: Systems over hope

You can’t control what Congress does. But you can control how prepared your lab is.

Start by auditing your current CLFS exposure. Which of your top 50 codes are on the cut list? How much revenue is tied to Medicare Part B? If you don’t know those numbers, you’re flying blind.

Next, tighten your front-end validation. The labs that survive reimbursement shocks are the ones with the cleanest claims. Every denied claim, missing modifier, and medical necessity failure becomes exponentially more expensive when your margins are compressed. Track your denial rate by payer weekly. Monitor your clean claim rate like a vital sign. The lab that spots patterns in week one keeps its cash flow intact. 

Finally, partner with a specialised lab billing company who understands laboratory reimbursement inside and out. Not a generalist RCM firm. You need a dependable partner like TransLabs that tracks CLFS policy changes, understands molecular coding nuances, and spots payer-specific denial patterns before they cost you six figures.

The labs that make it through 2027 won’t be the biggest. They’ll be the most prepared.

Amelia Hart, a psychology graduate from the University of Hertfordshire, has a keen interest in the fields of mental health, wellness, and lifestyle.